According to a Page One story in the March 3rd edition of The Wall Street Journal, "The Food and Drug Administration has bungled its effort to build a new system for detecting the side effects of medicines after they go on the market, delaying its implementation by at least four years, according to a report commissioned by the agency itself."
But what is entirely missing from the story (by the generally excellent reporter Anna Mathews) is that the FDA has never been given a budget to build a new system.
Want better adverse event reporting? Want better post-marketing surveillance? Want better data mining opportunities?
Show me the money!